vs
Apellis Pharmaceuticals, Inc.（APLS）与CALAVO GROWERS INC（CVGW）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是CALAVO GROWERS INC的1.6倍（$199.9M vs $124.7M），CALAVO GROWERS INC净利率更高（3.1% vs -29.5%，领先32.5%），Apellis Pharmaceuticals, Inc.同比增速更快（-5.9% vs -26.6%），CALAVO GROWERS INC自由现金流更多（$1.2M vs $-14.3M），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs -1.2%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
卡拉沃种植者公司是一家国际化农产消费品企业，核心业务涉及牛油果及其他鲜果、新鲜预制食品的包装与分销，产品面向全球各地的餐饮门店、零售卖场以及个人客户供应，是生鲜果蔬领域颇具规模的供应商。
APLS vs CVGW — 直观对比
营收规模更大
APLS
是对方的1.6倍
$124.7M
营收增速更快
APLS
高出20.7%
-26.6%
净利率更高
CVGW
高出32.5%
-29.5%
自由现金流更多
CVGW
多$15.5M
$-14.3M
两年增速更快
APLS
近两年复合增速
-1.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $124.7M |
| 净利润 | $-59.0M | $3.8M |
| 毛利率 | — | 9.3% |
| 营业利润率 | -25.6% | -1.4% |
| 净利率 | -29.5% | 3.1% |
| 营收同比 | -5.9% | -26.6% |
| 净利润同比 | -62.2% | 2846.0% |
| 每股收益（稀释后） | $-0.40 | $0.22 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSCVGW
| Q4 25 | $199.9M | $124.7M | ||
| Q3 25 | $458.6M | $178.8M | ||
| Q2 25 | $178.5M | $190.5M | ||
| Q1 25 | $166.8M | $154.4M | ||
| Q4 24 | $212.5M | $170.0M | ||
| Q3 24 | $196.8M | $179.6M | ||
| Q2 24 | $199.7M | $184.4M | ||
| Q1 24 | $172.3M | $127.6M |
净利润APLSCVGW
| Q4 25 | $-59.0M | $3.8M | ||
| Q3 25 | $215.7M | $4.7M | ||
| Q2 25 | $-42.2M | $6.8M | ||
| Q1 25 | $-92.2M | $4.4M | ||
| Q4 24 | $-36.4M | $-139.0K | ||
| Q3 24 | $-57.4M | $-732.0K | ||
| Q2 24 | $-37.7M | $6.1M | ||
| Q1 24 | $-66.4M | $-6.3M |
毛利率APLSCVGW
| Q4 25 | — | 9.3% | ||
| Q3 25 | — | 10.2% | ||
| Q2 25 | — | 9.5% | ||
| Q1 25 | — | 10.2% | ||
| Q4 24 | — | 9.7% | ||
| Q3 24 | — | 11.2% | ||
| Q2 24 | — | 11.1% | ||
| Q1 24 | — | 8.4% |
营业利润率APLSCVGW
| Q4 25 | -25.6% | -1.4% | ||
| Q3 25 | 48.7% | 4.8% | ||
| Q2 25 | -18.6% | 4.0% | ||
| Q1 25 | -50.0% | 3.3% | ||
| Q4 24 | -12.3% | 1.8% | ||
| Q3 24 | -24.0% | 5.2% | ||
| Q2 24 | -14.7% | 4.0% | ||
| Q1 24 | -36.0% | -2.4% |
净利率APLSCVGW
| Q4 25 | -29.5% | 3.1% | ||
| Q3 25 | 47.0% | 2.6% | ||
| Q2 25 | -23.6% | 3.6% | ||
| Q1 25 | -55.3% | 2.9% | ||
| Q4 24 | -17.1% | -0.1% | ||
| Q3 24 | -29.2% | -0.4% | ||
| Q2 24 | -18.9% | 3.3% | ||
| Q1 24 | -38.5% | -4.9% |
每股收益（稀释后）APLSCVGW
| Q4 25 | $-0.40 | $0.22 | ||
| Q3 25 | $1.67 | $0.26 | ||
| Q2 25 | $-0.33 | $0.38 | ||
| Q1 25 | $-0.74 | $0.25 | ||
| Q4 24 | $-0.30 | $-0.01 | ||
| Q3 24 | $-0.46 | $-0.04 | ||
| Q2 24 | $-0.30 | $0.34 | ||
| Q1 24 | $-0.54 | $-0.35 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $61.2M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $206.9M |
| 总资产 | $1.1B | $292.2M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSCVGW
| Q4 25 | $466.2M | $61.2M | ||
| Q3 25 | $479.2M | $63.8M | ||
| Q2 25 | $370.0M | $60.4M | ||
| Q1 25 | $358.4M | $48.5M | ||
| Q4 24 | $411.3M | $57.0M | ||
| Q3 24 | $396.9M | $1.1M | ||
| Q2 24 | $360.1M | $4.3M | ||
| Q1 24 | $325.9M | $5.7M |
总债务APLSCVGW
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $93.1M | — |
股东权益APLSCVGW
| Q4 25 | $370.1M | $206.9M | ||
| Q3 25 | $401.2M | $206.4M | ||
| Q2 25 | $156.3M | $206.6M | ||
| Q1 25 | $164.2M | $202.9M | ||
| Q4 24 | $228.5M | $200.3M | ||
| Q3 24 | $237.1M | $205.2M | ||
| Q2 24 | $264.3M | $207.3M | ||
| Q1 24 | $266.7M | $202.5M |
总资产APLSCVGW
| Q4 25 | $1.1B | $292.2M | ||
| Q3 25 | $1.1B | $301.2M | ||
| Q2 25 | $821.4M | $321.5M | ||
| Q1 25 | $807.3M | $298.9M | ||
| Q4 24 | $885.1M | $301.1M | ||
| Q3 24 | $901.9M | $382.4M | ||
| Q2 24 | $904.5M | $411.4M | ||
| Q1 24 | $831.9M | $394.7M |
负债/权益比APLSCVGW
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $2.3M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $1.2M |
| 自由现金流率自由现金流/营收 | -7.1% | 1.0% |
| 资本支出强度资本支出/营收 | 0.1% | 0.9% |
| 现金转化率经营现金流/净利润 | — | 0.60× |
| 过去12个月自由现金流最近4个季度 | $45.0M | $19.4M |
8季度趋势，按日历期对齐
经营现金流APLSCVGW
| Q4 25 | $-14.2M | $2.3M | ||
| Q3 25 | $108.5M | $8.0M | ||
| Q2 25 | $4.4M | $15.7M | ||
| Q1 25 | $-53.4M | $-4.4M | ||
| Q4 24 | $19.4M | $10.8M | ||
| Q3 24 | $34.1M | $11.4M | ||
| Q2 24 | $-8.3M | $2.1M | ||
| Q1 24 | $-133.0M | $58.0K |
自由现金流APLSCVGW
| Q4 25 | $-14.3M | $1.2M | ||
| Q3 25 | $108.3M | $7.3M | ||
| Q2 25 | $4.4M | $15.6M | ||
| Q1 25 | $-53.4M | $-4.7M | ||
| Q4 24 | $19.3M | $10.5M | ||
| Q3 24 | — | $11.3M | ||
| Q2 24 | $-8.4M | $745.0K | ||
| Q1 24 | $-133.3M | $-972.0K |
自由现金流率APLSCVGW
| Q4 25 | -7.1% | 1.0% | ||
| Q3 25 | 23.6% | 4.1% | ||
| Q2 25 | 2.5% | 8.2% | ||
| Q1 25 | -32.0% | -3.1% | ||
| Q4 24 | 9.1% | 6.2% | ||
| Q3 24 | — | 6.3% | ||
| Q2 24 | -4.2% | 0.4% | ||
| Q1 24 | -77.3% | -0.8% |
资本支出强度APLSCVGW
| Q4 25 | 0.1% | 0.9% | ||
| Q3 25 | 0.0% | 0.4% | ||
| Q2 25 | 0.0% | 0.1% | ||
| Q1 25 | 0.0% | 0.2% | ||
| Q4 24 | 0.0% | 0.2% | ||
| Q3 24 | 0.0% | 0.1% | ||
| Q2 24 | 0.0% | 0.7% | ||
| Q1 24 | 0.2% | 0.8% |
现金转化率APLSCVGW
| Q4 25 | — | 0.60× | ||
| Q3 25 | 0.50× | 1.69× | ||
| Q2 25 | — | 2.29× | ||
| Q1 25 | — | -1.00× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.35× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
CVGW
| Fresh Products | $104.7M | 84% |
| Segment Prepared | $14.5M | 12% |
| Tomatoes | $4.6M | 4% |
